Rapamycin increases mortality in db/db mice, a mouse model of type 2 diabetes

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 71, Issue 7, 2016, Pages 850-857

  Sataranatarajan, Kavithalakshmi ^a   Ikeno, Yuji ^a,b   Bokov, Alex ^a   Feliers, Denis ^a   Yalamanchili, Himabindu ^a   Lee, Hak Joo ^a   Mariappan, Meenalakshmi M ^a   Tabatabai Mir, Hooman ^a   Diaz, Vivian ^a   Prasad, Sanjay ^a   Javors, Martin A ^a   Choudhury, Goutam Ghosh ^a,b   Hubbard, Gene B ^a   Barnes, Jeffrey L ^a   Richardson, Arlan ^c   Kasinath, Balakuntalam S ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Life span; mTOR inhibition; Obesity; Toxicity

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ANIMAL; C57BL MOUSE; CAUSE OF DEATH; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; FEMALE; INFLAMMATION; LONGEVITY; MALE; METABOLISM; MORTALITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEX DIFFERENCE; TREATMENT OUTCOME;

ANIMALS; CAUSE OF DEATH; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LONGEVITY; MALE; MICE; MICE, INBRED C57BL; MORTALITY; SEX FACTORS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84979210064     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glv170     Document Type: Article

References (57)

1. Cafferkey R, McLaughlin MM, Young PR, Johnson RK, Livi GP. Yeast TOR (DRR) proteins: amino-acid sequence alignment and identification of structural motifs. Gene. 1994;141:133-136.
2. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756-758.
3. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78:35-43.
4. Caron E, Ghosh S, Matsuoka Y, et al. A comprehensive map of the mTOR signaling network. Mol Syst Biol. 2010;6:453. doi: 10.1038/msb.2010.108
5. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159-168.
6. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392-394. doi: 10.1038/nature08221
7. Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011;66:191-201. doi: 10.1093/gerona/glq178
8. Anisimov VN, Zabezhinski MA, Popovich IG, et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle. 2011;10:4230-4236. doi: 10.4161/cc.10.24.18486
9. Neff F, Flores-Dominguez D, Ryan DP, et al. Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest. 2013;123:3272-3291. doi: 10.1172/JCI67674
10. Miller RA, Harrison DE, Astle CM, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014;13:468-477. doi: 10.1111/acel.12194
11. Zhang Y, Bokov A, Gelfond J, et al. Rapamycin extends life and health in C57BL/6 mice. J Gerontol A Biol Sci Med Sci. 2014;69:119-130. doi: 10.1093/gerona/glt056
12. Fok WC, Chen Y, Bokov A, et al. Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. PLoS ONE. 2014;9:e83988. doi: 10.1371/journal.pone.0083988
13. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mor- tality in ApcDelta716 mice. Proc Natl Acad Sci U S A. 2008;105:13544-13549. doi: 10.1073/pnas.0800041105
14. Anisimov VN, Zabezhinski MA, Popovich IG, et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol. 2010;176:2092-2097. doi: 10.2353/ajpath.2010.091050
15. Ramos FJ, Chen SC, Garelick MG, et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med. 2012;4:144ra103. doi: 10.1126/scitranslmed.3003802
16. Komarova EA, Antoch MP, Novototskaya LR, et al. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging. 2012;4:709-714.
17. Livi CB, Hardman RL, Christy BA, et al. Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors. Aging. 2013;5:100-110.
18. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493:338-345. doi: 10.1038/nature11861
19. Hasty P, Livi CB, Dodds SG, et al. eRapa restores a normal life span in a FAP mouse model. Cancer Prev Res (Phila). 2014;7:169-178. doi: 10.1158/1940-6207.CAPR-13-0299
20. Comas M, Toshkov I, Kuropatwinski KK, et al. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging. 2012;4:715-722.
21. Bhattacharya A, Bokov A, Muller FL, et al. Dietary restriction but not rapamycin extends disease onset and survival of the H46R/H48Q mouse model of ALS. Neurobiol Aging. 2012;33:1829-1832. doi: 10.1016/j.neurobiolaging.2011.06.002
22. Zhang X, Li L, Chen S, et al. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy. 2011;7:412-424.
23. Caspersen CJ, Thomas GD, Boseman LA, Beckles GL, Albright AL. Aging, diabetes, and the public health system in the United States. Am J Public Health. 2012;102:1482-1497. doi: 10.2105/AJPH.2011.300616
24. Sataranatarajan K, Mariappan MM, Lee MJ, et al. Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am J Pathol. 2007;171:1733-1742.
25. Deblon N, Bourgoin L, Veyrat-Durebex C, et al. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol. 2012;165:2325-2340. doi: 10.1111/j.1476-5381.2011.01716.x
26. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335:1638-1643. doi: 10.1126/science.1215135
27. Gyurus E, Kaposztas Z, Kahan BD. Sirolimus therapy predisposes to newonset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant Proc. 2011;43:1583-1592. doi: 10.1016/j.transproceed.2011.05.001
28. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol. 2003;284:F1138-F1144.
29. Ikeno Y, Bronson RT, Hubbard GB, Lee S, Bartke A. Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. J Gerontol A Biol Sci Med Sci. 2003;58:291-296.
30. Ikeno Y, Hubbard GB, Lee S, et al. Housing density does not influence the longevity effect of calorie restriction. J Gerontol A Biol Sci Med Sci. 2005;60:1510-1517.
31. Ikeno Y, Hubbard GB, Lee S, et al. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci. 2009;64:522-529. doi: 10.1093/gerona/glp017
32. Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34:187-220.
33. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
34. Bates D, Chambers JM, Dalgaard P, et al. A Language and Environment for Statistical Computing, v2.15.3. Vienna, Austria: R Core Team; 2013. http://www.R-project.org/.
35. Therneau TM. A Package for Survival Analysis in S v2.37-2. Fochester, MN: Mayo Clinic; 2012.http://CRAN.R-project.org/package=survival.
36. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Berlin: Springer-Verlag; 2000.
37. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biom J. 2008;50:346-363. doi: 10.1002/bimj.200810425
38. Pinheiro JD, Bates DM. Mixed-effects Models in S and S-LUS. Berlin: Springer-Verlag; 2000.
39. Ladiges W, Ikeno Y, Liggitt D, Treuting PM. Pathology is a critical aspect of preclinical aging studies. Pathobiol Aging Age Relat Dis. 2013;3. doi: 10.3402/pba.v3i0.22451
40. Kobayashi K, Forte TM, Taniguchi S, Ishida BY, Oka K, Chan L. The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism. 2000;49:22-31.
41. Garris DR, Garris BL. Cytochemical analysis of pancreatic islet hypercytolipidemia following diabetes (db/db) and obese (ob/ob) mutation expression: influence of genomic background. Pathobiology. 2004;71:231-240.
42. Bokov AF, Garg N, Ikeno Y, et al. Does reduced IGF-1R signaling in Igf1r+/- mice alter aging? PLoS One. 2011;6:e26891. doi: 10.1371/journal.pone.0026891
43. Mandel MA, Mahmoud AA. Impairment of cell-mediated immunity in mutation diabetic mice (db/db). J Immunol. 1978;120:1375-1377.
44. Zhang Y, Ikeno Y, Bokov A, et al. Dietary restriction attenuates the accelerated aging phenotype of Sod1(-/-) mice. Free Radic Biol Med. 2013;60:300-306. doi: 10.1016/j.freeradbiomed.2013.02.026
45. Liao CY, Rikke BA, Johnson TE, Diaz V, Nelson JF. Genetic variation in the murine lifespan response to dietary restriction: from life extension to life shortening. Aging Cell. 2010;9:92-95. doi: 10.1111/j.1474- 9726.2009.00533.x
46. Davis RC, Schadt EE, Cervino AC, Peterfy M, Lusis AJ. Ultrafine mapping of SNPs from mouse strains C57BL/6J, DBA/2J, and C57BLKS/J for loci contributing to diabetes and atherosclerosis susceptibility. Diabetes. 2005;54:1191-1199.
47. Umemura A, Park EJ, Taniguchi K, et al. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab. 2014;20:133-144. doi: 10.1016/j.cmet.2014.05.001
48. Hinojosa CA, Mgbemena V, Van Roekel S, et al. Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence. Exp Gerontol. 2012;47:958-964. doi: 10.1016/j.exger.2012.08.013
49. Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6:268ra179. doi: 10.1126/scitranslmed.3009892
50. Wilkinson JE, Burmeister L, Brooks SV, et al. Rapamycin slows aging in mice. Aging Cell. 2012;11:675-682. doi: 10.1111/j.1474-9726.2012.00832.x
51. Houde VP, Brule S, Festuccia WT, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes. 2010;59:1338-1348. doi: 10.2337/db09-1324
52. Liu Y, Diaz V, Fernandez E, et al. Rapamyin-induced metabolic defects are transient in both lean and obese mice. Aging. 2014;6:742-754.
53. Tabatabai-Mir H, Sataranatarajan K, Lee HJ, et al. Rapamycin selectively alters serum chemistry in diabetic mice. Pathobiol Aging Age Relat Dis. 2012;2. doi: 10.3402/pba.v2i0.15896
54. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337-342.
55. Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008;8:157-168. doi: 10.1016/j.cmet.2008.06.011
56. Richardson A, Galvan V, Lin AL, Oddo S. How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story. Exp Gerontol. 2015; 68:164-176. doi: 10.1016/j.cmet.2008.06.011
57. Flynn JM, O'Leary MN, Zambataro CA, et al. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell. 2013;12:851-862. doi: 10.1111/acel.12109